Stefania DAtri
Overview
Explore the profile of Stefania DAtri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pallocca M, Molineris I, Berrino E, Marcozzi B, Betti M, Levati L, et al.
J Transl Med
. 2024 Oct;
22(1):958.
PMID: 39438964
No abstract available.
2.
Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini G, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):226.
PMID: 39143551
Background: Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. Here, plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseline...
3.
Ceci C, Ruffini F, Falconi M, Atzori M, Falzon A, Lozzi F, et al.
Biomed Pharmacother
. 2024 May;
176:116766.
PMID: 38788599
Activation of neuropilin-1 (NRP-1) by platelet derived growth factor (PDGF)-C sustains melanoma invasiveness. Therefore, in the search of novel agents capable of reducing melanoma spreading, PDGF-C/NRP-1 interaction was investigated as...
4.
Fortes C, Mastroeni S, Levati L, Alotto M, Ricci F, DAtri S
Genes Nutr
. 2024 May;
19(1):9.
PMID: 38783228
The role of inflammation in the aetiology of cancer is recognized. However, no study yet examined the association between an anti-inflammatory diet and cutaneous melanoma and explored whether it could...
5.
Pallocca M, Molineris I, Berrino E, Marcozzi B, Betti M, Levati L, et al.
J Transl Med
. 2024 Jan;
22(1):29.
PMID: 38184610
Background: The current therapeutic algorithm for Advanced Stage Melanoma comprises of alternating lines of Targeted and Immuno-therapy, mostly via Immune-Checkpoint blockade. While Comprehensive Genomic Profiling of solid tumours has been...
6.
Fragale A, Stellacci E, Romagnoli G, Licursi V, Parlato S, Canini I, et al.
Int J Cancer
. 2023 Jun;
153(5):1080-1095.
PMID: 37293858
BRAF mutations are the most common oncogenic alterations in melanoma cells, supporting proliferation, invasion, metastasis and immune evasion. In patients, these aberrantly activated cellular pathways are inhibited by BRAFi whose...
7.
Ruffini F, Ceci C, Atzori M, Caporali S, Levati L, Bonmassar L, et al.
Pharmacol Res
. 2023 May;
192:106782.
PMID: 37127213
Melanoma resistance to BRAF inhibitors (BRAFi) is often accompanied by a switch from a proliferative to an invasive phenotype. Therefore, the identification of signaling molecules involved in the development of...
8.
Tabolacci C, Giordano D, Rossi S, Cordella M, DArcangelo D, Moschella F, et al.
Molecules
. 2022 Nov;
27(22).
PMID: 36431901
Background: Despite recent improvements in therapy, the five-year survival rate for patients with advanced melanoma is poor, mainly due to the development of drug resistance. The aim of the present...
9.
Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini G, Bonmassar L, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954369
Despite the significant improvements in advanced melanoma therapy, there is still a pressing need for biomarkers that can predict patient response and prognosis, and therefore support rational treatment decisions. Here,...
10.
Picozza M, Cristofoletti C, Bresin A, Fioretti M, Sambucci M, Scala E, et al.
J Invest Dermatol
. 2022 May;
142(11):3009-3019.e9.
PMID: 35533722
Sézary syndrome (SS) is a rare and aggressive variant of cutaneous T-cell lymphoma. It is characterized by the copresence of CD4+ neoplastic lymphocytes, named Sezary cells, mainly in the blood,...